Pathology billing demands precise specimen-level coding, meticulous TC/PC modifier management, and continuous adaptation to evolving molecular and genomic code sets—where a single misclassification can result in claim denial or audit exposure. VeriMedix delivers the coding accuracy and compliance oversight that pathology groups and hospital-based pathologists need to sustain revenue in an increasingly scrutinized specialty.
Pathology billing is fundamentally specimen-driven. Surgical pathology CPT codes 88300–88309 are selected based on the tissue specimen type and the depth of examination required (gross only vs. gross and microscopic), not simply the diagnosis. Code 88305 (Level IV – gross and microscopic examination) is the most commonly used surgical pathology code, covering a large range of specimens including breast biopsies, bone marrow biopsies, and colon biopsies. Higher-level codes such as 88307 (Level V) and 88309 (Level VI) apply to more complex resections. The critical compliance requirement is that coding must match the actual specimen examined and the level of physician work performed—not a default code assignment. One important exception: prostate needle biopsy specimens must be reported with HCPCS G0416 rather than 88305 per CMS and most major commercial payer policies.
The professional component (PC) vs. technical component (TC) distinction is central to pathology billing. When a pathologist employed by a hospital uses the hospital's laboratory infrastructure, the hospital bills the TC under its own NPI and the pathologist's group bills the PC with modifier 26. When a pathologist owns or operates a freestanding laboratory and personally performs both the lab work and interpretation, the global fee (no modifier) is appropriate. Misapplying or omitting these modifiers causes claim underpayment or duplicate billing. Additional complexity arises with special stains (88312–88313), immunohistochemistry (88342–88344), and in situ hybridization (88364–88377), which each have their own coding rules, units-of-service definitions, and NCCI bundling restrictions.
Molecular pathology—Tier 1 (81162–81383 gene-specific codes) and Tier 2 (81400–81408 codes requiring analyte specification)—presents ongoing billing challenges. Proprietary Laboratory Analyses (PLA) U-codes now apply to many single-source molecular assays, and providers who bill a generic Tier 2 code when an applicable PLA code exists face payer recoupment. The MolDX program operated by Palmetto GBA manages coverage and technical assessments for next-generation sequencing panels (81445, 81450, 81455) in Medicare, requiring pre-approval before billing. Modifier 91 is used when the same test is legitimately repeated on the same date for a new clinical result—not for quality control repeats. CLIA laboratory certification must remain current, as CMS edits claims against CLIA certificate status.
Below are commonly billed codes our certified coders manage for pathology practices. Always confirm payer-specific coverage and current code values.
| Code | Description | Billing note |
|---|---|---|
88300 | Level I – Surgical pathology, gross examination only | Least complex; use for non-neoplastic tissue that requires only gross inspection |
88302 | Level II – Surgical pathology, gross and microscopic examination | E.g., appendix incidental to appendectomy, fallopian tube for ligation |
88304 | Level III – Surgical pathology, gross and microscopic examination | E.g., abortion (missed/spontaneous), artery biopsy, bone exostosis |
88305 | Level IV – Surgical pathology, gross and microscopic examination | Most commonly billed; includes breast biopsy (no margin eval), colon biopsy, bone marrow biopsy, cervical biopsy, skin shave biopsy |
88307 | Level V – Surgical pathology, gross and microscopic examination | E.g., breast resection with margin evaluation, colon segmental resection for non-neoplastic condition, lung wedge resection |
88309 | Level VI – Surgical pathology, gross and microscopic examination | Most complex; e.g., colon resection for tumor, radical prostatectomy, total cystectomy |
G0416 | Surgical pathology, gross and microscopic examination, prostate needle biopsy (HCPCS) | Required by CMS and most commercial payers instead of 88305 for all prostate needle biopsy specimens; report as one unit regardless of specimen count |
88342 | Immunohistochemistry (IHC) or immunocytochemistry, per specimen; initial single antibody stain procedure | Bill one unit per antibody per specimen; use 88341 for each additional antibody on same specimen |
81445 | Targeted genomic sequence analysis panel, solid organ neoplasm, 5–50 genes | Requires current MolDX program approval for Medicare billing; document tumor type and panel composition |
Our standard operating procedures for pathology revenue cycle management — the step-by-step workflow we follow on every claim:
These are the issues we see most often in pathology billing — and exactly how we resolve them:
CMS and UnitedHealthcare (and most major payers) require HCPCS G0416 for prostate needle biopsy specimens instead of 88305. G0416 is one unit regardless of how many cores are examined. Submitting 88305 results in denial or recoupment. Fix: add a claim scrubbing rule that automatically substitutes G0416 when the specimen source field contains prostate needle biopsy and the payer is Medicare or a G0416-mandating commercial plan.
A pathologist in a hospital-employed arrangement who bills the global fee (no modifier) causes the payer to deny the claim as a duplicate when the hospital also submits the TC. Conversely, a pathologist in a freestanding lab who mistakenly bills only modifier 26 receives less than the global rate. Fix: build a billing rule keyed to place of service and provider employment arrangement that auto-applies or suppresses TC/26 modifiers accordingly.
Billing multiple individual Tier 2 or Tier 1 codes when a panel-level code (81445, 81450, 81455) or PLA U-code exists constitutes unbundling and is subject to Medicare recoupment. This was highlighted in a CMS billing guidance article as a systematic industry error. Fix: implement a quarterly PLA code update review; maintain a code crosswalk from proprietary assay names to applicable Tier 1/PLA codes; require pre-submission review for all molecular claims above a set dollar threshold.
Modifier 91 is valid only when a test is clinically necessary to repeat on the same date to obtain a new result (e.g., serial troponins, lactate trending). Appending 91 to a repeat driven by instrument malfunction, QC failure, or sample dilution is incorrect and will not survive audit. Fix: train lab billing staff on the clinical documentation required for modifier 91 and require the ordering physician's clinical rationale to be documented before modifier 91 is applied.
Molecular pathology claims rejected for missing or unsupported ICD-10 codes are a top denial reason. CMS requires that the ordering physician's requisition include a diagnosis code and that the clinical record support medical necessity—including why the test result would influence clinical management. Fix: create disease-specific ICD-10 code suggestion lists for common molecular test orders; require the ordering provider to confirm the clinical indication at time of requisition.
Verimedix works inside the systems pathology practices already use, including:
Multiple units of 88305 may be billed when multiple separately identifiable specimens are submitted for examination on the same date. Each distinct specimen (e.g., left colon biopsy, right colon biopsy, rectal biopsy) is a separate billable unit. However, CMS and most payers apply MUEs (Medically Unlikely Edits) for same-day units; claims exceeding typical volumes may be flagged for review. All specimens must be separately accessioned and reported.
The global fee (no modifier) is appropriate when the pathologist performs both the technical work (specimen processing, staining) and the professional interpretation, and when the pathologist owns or controls the laboratory. The professional component only (modifier 26) is billed when the pathologist's employer is a hospital or an entity that separately bills the TC. The facility or reference lab bills TC. Billing both a global fee and TC for the same specimen by different entities constitutes double-billing.
MolDX is a program managed by Palmetto GBA (and applied in other MAC jurisdictions) that establishes coverage criteria and technical assessments for complex molecular diagnostic tests, including next-generation sequencing (NGS) panels. Laboratories billing CPT codes 81445, 81450, 81455, or proprietary PLA codes under Medicare must obtain MolDX approval before billing. Submitting these codes without current MolDX approval results in automatic denial. Approval requires submission of technical documentation including analytic validity, clinical validity, and clinical utility evidence.
Yes. Codes 88321–88325 describe surgical pathology consultation services where a pathologist reviews material prepared and initially interpreted elsewhere. These codes cannot be billed by pathologists in the same provider group who originally interpreted the material. Additionally, when billing 88321–88325, do not separately bill for staining procedures (88312, 88313, 88342, etc.) on the same material unless staining was newly performed and separately documented. CMS NCCI guidelines restrict bundling between these code families.
CPT 88342 is billed for the first IHC antibody stain per specimen. CPT 88341 is an add-on code for each additional antibody stain on the same specimen, reported with 88342 as the primary code. A single unit per antibody per specimen applies—you cannot bill 88342 twice for the same antibody on the same specimen. If quantitative or semi-quantitative IHC is performed, use 88360 (manual) or 88361 (digital image analysis). NCCI edits restrict simultaneous billing of 88342 with certain consultation codes; review NCCI tables before submitting.
CMS validates laboratory claims against the CLIA certificate associated with the billing NPI. If a lab's CLIA certificate has lapsed, been revoked, or doesn't cover the complexity level of the tests billed, claims will be denied. CLIA-waived tests billed from a facility with only a Certificate of Waiver do not need modifier QW under CMS rules, but some MAC and commercial payer edits require it. Labs must maintain current certification for every site where testing is performed and ensure each site's NPI is linked to a valid CLIA number.
CMS introduced codes for AI-assisted diagnostic procedures (e.g., Category III codes) beginning in the 2025 CPT cycle. However, many of these do not yet have CMS payment values assigned. Digital whole-slide imaging interpretation is generally not separately billable from the underlying surgical pathology code at this time; it is considered part of the professional work. Monitor annual CPT and Medicare Physician Fee Schedule updates for emerging coverage of digital and AI pathology services.
Verimedix handles the entire pathology revenue cycle — coding, submission, denials, and A/R — so your team can focus on patients.